tiprankstipranks
Trending News
More News >
Linical Co., Ltd. (JP:2183)
:2183
Japanese Market

Linical Co., Ltd. (2183) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Linical Co., Ltd.

(2183)

Rating:54Neutral
Price Target:
¥311.00
▼(-4.60%Downside)
The overall stock score is primarily influenced by moderate financial performance with declining revenues and losses. Technical analysis indicates moderate positive momentum, while valuation reflects challenges with negative earnings but a high dividend yield. The absence of significant earnings call insights and corporate events limits additional impacts on the score.

Linical Co., Ltd. (2183) vs. iShares MSCI Japan ETF (EWJ)

Linical Co., Ltd. Business Overview & Revenue Model

Company DescriptionLinical Co., Ltd. is a global contract research organization (CRO) that specializes in providing comprehensive clinical trial services to pharmaceutical, biotechnology, and medical device companies. The company is headquartered in Japan and operates across various regions, including Asia, Europe, and North America. Linical offers a wide range of services, including clinical development, post-marketing surveillance, and data management, focusing on therapeutic areas such as oncology, neurology, and immunology.
How the Company Makes MoneyLinical Co., Ltd. generates revenue primarily through service fees charged for its clinical trial management and related services. The company partners with pharmaceutical, biotechnology, and medical device companies to conduct clinical trials, from planning and execution to data analysis and regulatory submissions. Linical's key revenue streams include fees from conducting clinical trials, consulting services, and post-marketing surveillance activities. The company benefits from long-term partnerships and collaborations with its clients, which provide a steady flow of projects and revenue. Linical's global presence allows it to cater to a diverse client base and leverage regional expertise in regulatory requirements and market dynamics.

Linical Co., Ltd. Financial Statement Overview

Summary
Linical Co., Ltd. exhibits challenges in profitability with declining revenues and losses impacting the income statement. The balance sheet remains stable with moderate leverage and strong liquidity. Cash flows are positive but declining, underscoring the need for improved operational performance to sustain financial health.
Income Statement
40
Negative
The income statement shows declining performance with total revenue decreasing from the previous year, leading to negative net income in the latest period. The gross profit margin is approximately 19.23%, but the net profit margin is negative due to the loss. Revenue growth has been inconsistent, with a significant drop in the most recent period, and EBIT and EBITDA margins have deteriorated.
Balance Sheet
55
Neutral
The balance sheet indicates moderate strength with a stable equity base, though the debt-to-equity ratio is approximately 0.32, suggesting moderate leverage. The equity ratio is around 43.24%, providing a reasonable cushion against liabilities. However, the net debt position is negative, indicating strong liquidity.
Cash Flow
60
Neutral
Cash flow analysis reveals declining free cash flow, but it remains positive. Free cash flow to net income ratio is not applicable due to negative net income, but the operating cash flow to net income ratio is positive, indicating operational cash generation despite financial losses.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue11.01B10.44B12.31B12.52B11.56B10.28B
Gross Profit2.57B2.01B3.78B4.16B3.61B2.77B
EBITDA206.58M40.97M1.20B1.89B1.50B801.38M
Net Income-232.20M-539.10M338.27M1.00B790.49M539.97M
Balance Sheet
Total Assets17.40B16.78B18.54B17.46B15.72B15.28B
Cash, Cash Equivalents and Short-Term Investments6.77B7.04B7.47B7.04B5.99B5.08B
Total Debt2.43B2.33B2.90B3.54B4.10B4.69B
Total Liabilities9.72B9.52B10.30B9.88B9.17B9.57B
Stockholders Equity7.68B7.25B8.24B7.58B6.54B5.71B
Cash Flow
Free Cash Flow0.00602.21M1.03B1.83B1.59B-44.89M
Operating Cash Flow0.00605.10M1.06B1.84B1.63B23.61M
Investing Cash Flow0.00-54.93M-28.00M-14.19M20.76M169.00M
Financing Cash Flow0.00-939.22M-960.92M-957.33M-951.55M-329.56M

Linical Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price326.00
Price Trends
50DMA
311.16
Positive
100DMA
311.95
Positive
200DMA
327.82
Positive
Market Momentum
MACD
4.75
Positive
RSI
57.59
Neutral
STOCH
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2183, the sentiment is Positive. The current price of 326 is above the 20-day moving average (MA) of 323.80, above the 50-day MA of 311.16, and below the 200-day MA of 327.82, indicating a bullish trend. The MACD of 4.75 indicates Positive momentum. The RSI at 57.59 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2183.

Linical Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
¥343.76B10.59-2.88%2.57%11.81%-7.17%
55
Neutral
¥10.67B
109.03%98.53%
54
Neutral
¥7.45B
4.85%-15.20%-259.37%
54
Neutral
¥7.76B55.07
-92.17%-1648.96%
47
Neutral
¥8.23B-148.36%22.93%47.73%
41
Neutral
¥7.10B
-97.61%14.80%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2183
Linical Co., Ltd.
328.00
-92.06
-21.92%
JP:3750
Cytori Cell Research Institute, Inc.
862.00
-103.00
-10.67%
JP:4584
Kidswell Bio Corporation
229.00
93.00
68.38%
JP:4893
Noile-Immune Biotech Inc.
171.00
-28.00
-14.07%
JP:4564
OncoTherapy Science
27.00
-9.00
-25.00%

Linical Co., Ltd. Corporate Events

Linical Co., Ltd. Announces Year-End Dividend Distribution
Jun 2, 2025

Linical Co., Ltd. announced a resolution to distribute retained earnings, declaring a year-end dividend of JPY 16.00 per share for the fiscal year ended March 31, 2025. This decision reflects the company’s commitment to balancing corporate growth with shareholder returns, as dividends are paid from retained earnings based on board resolutions.

Linical Co., Ltd. Reports Financial Downturn with Optimistic Forecast for 2026
May 15, 2025

Linical Co., Ltd. reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 15.2% and a net loss of ¥539 million. Despite the downturn, the company forecasts a recovery in the next fiscal year with an expected 7.3% increase in net sales and a return to profitability.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 29, 2025